Robert Andrews — CEO

The majority of my patent work is in biopharma, with a focus on cancer therapies and immuno-oncology. I am particularly interested in Antibody-Drug Conjugate (ADC) technology, and I have supported ADC companies all the way from start-up to first drug approval. In that time I've tracked the development of the ADC sector, and am excited to be a part of it in the current 'golden age' of innovation and value generation. "𝑬𝒙𝒄𝒆𝒑𝒕𝒊𝒐𝒏𝒂𝒍 𝒂𝒘𝒂𝒓𝒆𝒏𝒆𝒔𝒔 𝒇𝒓𝒐𝒎 𝒕𝒉𝒆 𝒍𝒆𝒂𝒅 𝒑𝒂𝒓𝒕𝒏𝒆𝒓 𝑹𝒐𝒃𝒆𝒓𝒕 𝑨𝒏𝒅𝒓𝒆𝒘𝒔 𝒘𝒊𝒕𝒉 𝒄𝒐𝒓𝒓𝒆𝒔𝒑𝒐𝒏𝒅𝒊𝒏𝒈𝒍𝒚 𝒑𝒓𝒂𝒄𝒕𝒊𝒄𝒂𝒍, 𝒑𝒓𝒂𝒈𝒎𝒂𝒕𝒊𝒄 𝒂𝒅𝒗𝒊𝒄𝒆. 𝑯𝒆 𝒂𝒑𝒑𝒆𝒂𝒓𝒔 𝒕𝒐 𝒓𝒆𝒑𝒓𝒆𝒔𝒆𝒏𝒕 𝒂 𝒈𝒐𝒐𝒅 𝒔𝒆𝒍𝒆𝒄𝒕𝒊𝒐𝒏 𝒐𝒇 𝒄𝒍𝒊𝒆𝒏𝒕𝒔 𝒊𝒏 𝒕𝒉𝒆 𝒔𝒆𝒄𝒕𝒐𝒓 𝒂𝒏𝒅 𝒉𝒊𝒔 𝒄𝒐𝒎𝒃𝒊𝒏𝒆𝒅 𝒆𝒙𝒑𝒆𝒓𝒊𝒆𝒏𝒄𝒆 𝒊𝒔 𝒗𝒆𝒓𝒚 𝒎𝒖𝒄𝒉 𝒕𝒐 𝒐𝒖𝒓 𝒃𝒆𝒏𝒆𝒇𝒊𝒕." [Nick Finnie, Head of IP, ADC Therapeutics] “𝑻𝒉𝒆𝒓𝒆 𝒂𝒓𝒆𝒏’𝒕 𝒎𝒂𝒏𝒚 𝑷𝒂𝒕𝒆𝒏𝒕 𝑨𝒕𝒕𝒐𝒓𝒏𝒆𝒚𝒔 𝒂𝒔 𝒌𝒏𝒐𝒘𝒍𝒆𝒅𝒈𝒆𝒂𝒃𝒍𝒆 𝒂𝒏𝒅 𝒆𝒙𝒄𝒊𝒕𝒆𝒅 𝒂𝒃𝒐𝒖𝒕 𝒕𝒉𝒆 𝑨𝑫𝑪 𝒇𝒊𝒆𝒍𝒅.” [CSO, UK ADC SME] ------------------------------------------------ As Mewburn' Chief Inclusion & Diversity Officer, I lead the firm’s focus on I&D. An important part of that role is developing and executing our I&D strategy, and providing the link between our management team and the groups and individuals whose day-to-day enthusiasm brings our strategy to life. ------------------------------------------------ Another area of interest is the Korean biopharma sector. My interest was kindled during a period of several months living and working in Seoul, where I've made many friends. In the subsequent decade I have had the opportunity to work with a growing number of companies in this dynamic sector, which happily takes me back to Seoul regularly. ------------------------------------------------ If any of these topics chime with you, please reach out to connect. It's always a pleasure to meet new people who share a passion.

Stackforce AI infers this person is a Biopharma IP Strategist with a focus on Inclusion & Diversity.

Location: London, United Kingdom

Experience: 12 yrs 4 mos